CA2118938A1 - Recepteur a gaba-a avec sites de fixation pour steroides - Google Patents

Recepteur a gaba-a avec sites de fixation pour steroides

Info

Publication number
CA2118938A1
CA2118938A1 CA002118938A CA2118938A CA2118938A1 CA 2118938 A1 CA2118938 A1 CA 2118938A1 CA 002118938 A CA002118938 A CA 002118938A CA 2118938 A CA2118938 A CA 2118938A CA 2118938 A1 CA2118938 A1 CA 2118938A1
Authority
CA
Canada
Prior art keywords
gnr
dhp
binding
grc
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002118938A
Other languages
English (en)
Inventor
Kelvin W. Gee
Nancy T. Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cocensys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2118938A1 publication Critical patent/CA2118938A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CA002118938A 1991-09-13 1992-09-09 Recepteur a gaba-a avec sites de fixation pour steroides Abandoned CA2118938A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75951291A 1991-09-13 1991-09-13
US759,512 1991-09-13

Publications (1)

Publication Number Publication Date
CA2118938A1 true CA2118938A1 (fr) 1993-04-01

Family

ID=25055930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002118938A Abandoned CA2118938A1 (fr) 1991-09-13 1992-09-09 Recepteur a gaba-a avec sites de fixation pour steroides

Country Status (5)

Country Link
EP (1) EP0603312A4 (fr)
JP (1) JPH06510999A (fr)
AU (1) AU2657292A (fr)
CA (1) CA2118938A1 (fr)
WO (1) WO1993005786A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
AU691905B2 (en) * 1994-02-14 1998-05-28 Purdue Pharma Ltd. Androstanes and pregnanes for allosteric modulation of GABA receptor
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT808325E (pt) * 1994-11-23 2001-06-29 Cocensys Inc Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997003677A1 (fr) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone
EP0980384A1 (fr) * 1997-05-02 2000-02-23 American Home Products Corporation Pregnan 3,20 diol mono- et di-sulfates
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
WO2014169831A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
EP2986624B1 (fr) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. Stéroïdes neuroactifs 19-nor et pour l'utilisation thérapeutique
DK3021852T3 (da) 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
WO2015027227A1 (fr) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions et utilisations
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
TWI762436B (zh) 2014-10-16 2022-05-01 美商賽吉醫療公司 用於治療中樞神經系統（ｃｎｓ）病症之組合物及方法
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
DK3224269T3 (da) 2014-11-27 2020-05-25 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2017156103A1 (fr) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions, et leurs utilisations
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.

Also Published As

Publication number Publication date
EP0603312A1 (fr) 1994-06-29
JPH06510999A (ja) 1994-12-08
WO1993005786A1 (fr) 1993-04-01
AU2657292A (en) 1993-04-27
EP0603312A4 (fr) 1995-06-07

Similar Documents

Publication Publication Date Title
CA2118938A1 (fr) Recepteur a gaba-a avec sites de fixation pour steroides
Lambert et al. Neurosteroid modulation of native and recombinant GABA A receptors
Paul et al. Neuroactive steroids
Belelli et al. Anticonvulsant steroids and the GABA/benzodiazepine receptor-chloride ionophore complex
Lan et al. Differential responses of expressed recombinant human γ‐aminobutyric acidA receptors to neurosteroids
Lambert et al. Modulation of native and recombinant GABAA receptors by endogenous and synthetic neuroactive steroids
Belelli et al. Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one
Losel et al. Nongenomic steroid action: controversies, questions, and answers
Gee Steroid modulation of the GABA/benzodiazepine receptor-linked chloride lonophore
Hamon et al. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the β subunit
Majewska et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor
Wehling Specific, nongenomic actions of steroid hormones
Melchior et al. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze
Lopez et al. Interaction of caffeine with the GABAA receptor complex: Alterations in receptor function but not ligand binding
Martin et al. GABA receptors
Bell-Horner et al. Influence of subunit configuration on the interaction of picrotoxin-site ligands with recombinant GABAA receptors
Lambert et al. The selective interaction of neurosteroids with the GABAA receptor
Drugan et al. Decreased forebrain [35S] TBPS binding and increased [3H] muscimol binding in rats that do not develop stress-induced behavioral depression
Ziolkowski et al. A neuroactive steroid with a therapeutically interesting constellation of actions at GABAA and NMDA receptors
Hauser et al. Modulation of recombinant α6β2γ2 GABAA receptors by neuroactive steroids
Rybczynski et al. γ-Aminobutyrate-A Receptor Modulation by 3-Aryl-1-(arylsulfonyl)-1, 4, 5, 6-tetrahydropyridazines
McAuley et al. Modulation of [3H] flunitrazepam binding by natural and synthetic progestational agents
Radulescu et al. Nuclear colocalization and complex formation of insulin with retinoblastoma protein in HepG2 human hepatoma cells
JPH03500049A (ja) ストレス、不安および発作活性の緩和のための組成物および方法
Itier et al. Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons

Legal Events

Date Code Title Description
FZDE Dead